You are here

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Last updated on August 22, 2018

FOR MORE INFORMATION
Study Location
UC Davis Dermatology
Sacramento, California, 95816 United States
Contact
1-800-254-6398
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male subjects, healthy female subjects of non-childbearing potential, 18-55
years of age (Part 1)

- Male subjects, female subjects of non-childbearing potential, female subjects of
childbearing potential with documented bilateral tubal ligation (tubes tied) or
bilateral salpingectomy (tubes removed), 18-65 years of age, and 2 of the following
symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or
reduction/loss of smell (Part 2)

- Male or female subjects between the ages of 18 and 75 years, inclusive with
moderate-to-severe Atopic Dermatitis, agree to avoid prolonged exposure to the sun and
not to use tanning booths, sun lamps, or other ultraviolet light sources during the
study (Part 3)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.),
positive urine drug test, fever within 7 days of dosing, active infections within 28
days of dosing (Part 1 and 2 and 3)

- History of allergic reaction to topical lidocaine, nasal surgery within 6 months (Part
2)

- Exposure to live or attenuated vaccines, have skin conditions other than Atopic
Dermatitis, use of JAK inhibitors and biologics (Part 3)

NCT02743871
Pfizer
Recruiting
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Healthy Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
mCRPC With DNA Damage Repair Deficiencies (DDR)
NCT03395197
Males
18+
Years
Multiple Sites
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And/or Multiple Intravenous And/or Subcutaneous Doses Of Pf-06817024 In Healthy Subjects Who May Be Mildly Atopic, Subjects With Chronic Rhinosinusitis With Nasal Polyps, And Subjects With Moderate-severe Atopic Dermatitis
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with moderate-to-severe Atopic Dermatitis

The purpose of the study for Part 1 is to evaluate the safety and tolerability of PF-06817024 in healthy subjects.

The purpose of the study for Part 2 is to evaluate the safety and tolerability of PF-06817024 in patients with chronic rhinosinusitis with nasal polyps.

The purpose of the study for Part 3 is to evaluate the safety and tolerability of PF-06817024 in patients with moderate-to-severe Atopic Dermatitis

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Healthy
  • Chronic Rhinosinusitis With Nasal Polyps
  • Atopic Dermatitis
  • Biological: PF-06817024
    Subjects will be given one dose of PF-06817024 intravenously
  • Other: Placebo for PF-06817024
    Subjects will be given one dose of placebo for PF-06817024 intravenously
  • Biological: PF-06817024
    Subjects will be given one dose of PF-06817024 subcutaneously
  • Other: Placebo for PF-06817024
    Subjects will be given one dose of placebo for PF-06817024 subcutaneously
  • Biological: PF-06817024
    Subjects will be given two doses of PF-06817024 intravenously
  • Other: Placebo for PF-06817024
    Subjects will be given two doses of PF-06817024 intravenously
  • Biological: PF-06817024
    Subjects will be given 2 doses intravenously
  • Other: Placebo for PF-06817024
    Subjects will be given 2 doses intravenously
  • Biological: PF-06817024
    Subjects will be given doses of PF-06817024 intravenously
  • Other: Placebo for PF-06817024
    Subjects will be given doses of Placebo intravenously
  • Experimental: Cohort 1
    10 mg of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 2
    30 mg of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 3
    100 mg of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 4
    300 mg of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 5
    1000 mg of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 6
    2000 mg of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 7
    30 mg subcutaneous dose of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 8
    300 mg of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 9
    IV dose to be determined of PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 10
    PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 11
    PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 12
    PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
  • Experimental: Cohort 13
    PF-06817024 or placebo
    Interventions:
    • Biological: PF-06817024
    • Other: Placebo for PF-06817024
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
145
May 13, 2020
May 13, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Healthy male subjects, healthy female subjects of non-childbearing potential, 18-55 years of age (Part 1)
  • Male subjects, female subjects of non-childbearing potential, female subjects of childbearing potential with documented bilateral tubal ligation (tubes tied) or bilateral salpingectomy (tubes removed), 18-65 years of age, and 2 of the following symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or reduction/loss of smell (Part 2)
  • Male or female subjects between the ages of 18 and 70 years, inclusive with moderate-to-severe Atopic Dermatitis, agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps, or other ultraviolet light sources during the study (Part 3)

Exclusion Criteria:

  • Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.), positive urine drug test, fever within 7 days of dosing, active infections within 28 days of dosing (Part 1 and 2 and 3)
  • History of allergic reaction to topical lidocaine, nasal surgery within 6 months (Part 2)
  • Exposure to live or attenuated vaccines, have skin conditions other than Atopic Dermatitis, use of JAK inhibitors and biologics (Part 3)
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Yes

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
United States
 
 
NCT02743871
C0341001
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description:

Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...

Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now